Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

The pharmaceutical industry is criticizing the Trump administration’s plan for carrying out a critical round of Biden-era ...

The sweeping One Big Beautiful Bill Act, signed into federal law July 4, amended CMS’ drug price negotiations authority that could absolve nearly $5 billion in projected savings, according to the ...

Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.